Psychological distress (depression and anxiety) in people with head and neck cancers
Kate A Neilson, Annabel C Pollard, Ann M Boonzaier, June Corry, David J Castle, Karen R Mead, Marcelle CL Gray, David I Smith, Tom Trauer, Jeremy W Couper
Medical Journal of Australia | WILEY | Published : 2010
Kate Neilson was the recipient of a Psycho-Oncology Research Co-Operative travel grant. David Castle has had Board membership relating to the medications Lexapro (Lundbeck Australia), Zyprexa (Eli Lilly), Ability (Bristol-Myers Squibb), Desvenlafaxine (Wyeth), Varenicline (Pfizer), Asenapine (Schering-Plough) and has been on the Bipolar Advisory Board for Janssen-Cilag Australia; he has also received grants or has grants pending from Eli Lilly, Janssen-Cilag, Roche, Bristol-Myers Squibb, Pfizer, and Lundbeck; he had had travel and accommodation paid by Eli Lilly, Bristol-Myers Squibb, Astra-Zeneca, Lundbeck Australia, Janssen-Cilag, Pfizer, Organon, Sanofi-Aventis, and Wyeth.